Pharsight

1. Recorlev patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098877	STRONGBRIDGE	Methods and compositions for treating diabetes, metabolic syndrome and other conditions	Jan, 2026 (2 years from now)
US10835530	STRONGBRIDGE	Methods and compositions for treating diabetes, metabolic syndrome and other conditions	Jan, 2026 (2 years from now)
US10517868	STRONGBRIDGE	Methods and compositions for treating diabetes, metabolic syndrome and other conditions	Jan, 2026 (2 years from now)
US9918984	STRONGBRIDGE	Methods and compositions for treating diabetes, metabolic syndrome and other conditions	Jan, 2026 (2 years from now)
US11478471	STRONGBRIDGE	NA	Jan, 2026 (2 years from now)
US11278547	STRONGBRIDGE	Methods of treating disease with levoketoconazole	Mar, 2040 (16 years from now)
US11020393	STRONGBRIDGE	Methods of treating disease with levoketoconazole	Mar, 2040 (16 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of ...

Dosage: TABLET;ORAL